SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 5

Parvovirus B19 seroprevalence in Turkish blood donors

Şeniz GÖRAL
İdil YENİCESU
Gülendam BOZDAYI
Aysu DUYAN ÇAMURDAN
Aylin ALTAY KOÇAK
Pages
956–960
Publication Date
2018-10-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it is thought that the results obtained from this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Parvovirus risk in blood transfusion has become a popular research topic since there are limited data on parvovirus seroprevalence in blood donors in Turkey.
📊
Key Findings & Data:Materials and methods: Blood samples of 988 blood donors admitted to a university blood bank were obtained for parvovirus B19 IgM and IgG detection.
💡
Conclusion & Impact:Therefore, it is thought that the results obtained from this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Transfusion medicine · ELISA · blood banking

Abstract

Background/aim: Parvovirus risk in blood transfusion has become a popular research topic since there are limited data on parvovirus seroprevalence in blood donors in Turkey. The aim of this study was to investigate parvovirus seroprevalence in blood donors in Turkey. Materials and methods: Blood samples of 988 blood donors admitted to a university blood bank were obtained for parvovirus B19 IgM and IgG detection. The samples were analyzed using the ELISA method. Results: IgM positivity of 3.92% and IgG positivity of 58.9% was detected in the blood samples. Parvovirus IgM positivity was found to be the highest in the age group of 41-50 years (P = 0.045) and IgG positivity was detected to be the highest in the age group of 31-40 years (P < 0.001). Parvovirus IgG positivity was significantly higher in women (P = 0.041). However, there was no difference regarding parvovirus IgM positivity in terms of sex (P = 0.245). Conclusion: Although this study does not represent the whole country, it is still the largest investigation carried out on the topic in Turkey and the obtained results are generally similar to those of European countries. Therefore, it is thought that the results obtained from this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.

🔖

Cite This Article

GÖRAL, Ş., YENİCESU, İ., BOZDAYI, G., ÇAMURDAN, A. D., KOÇAK, A. A. (2018). Parvovirus B19 seroprevalence in Turkish blood donors. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 5, 956–960. https://ajindex.com/articles/113471

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gallinella G. Parvovirus B19 achievements and challenges. ISRN Virol 2013; 2013: 898730. Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. P Natl Acad Sci USA 2004; 101, 32: 11628-11633.
  2. Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, Siennicka J, Trzcinska A, Van Damme P, Beutels P et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol Infect 2008; 136: 1059-1068.
  3. Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53: 459-475.
  4. Marano G, Vaglio S, Pupella S, Facco G, Calizzani G, Candura F, Liumbruno GM, Grazzini G. Human parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus 2015; 13: 184-196.
  5. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998; 26: 89-94.
  6. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204.
  7. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011; 51: 1887-1895.
  8. Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R et al. Parvovirus B19 revised. Transfus Med Hemother 2010; 37: 339-350.
  9. Goeyvaerts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, Van Damme P, Beutels P. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Stat Soc 2010; 13: 255-277. US Food and Drug Administration. Guidance for Industry: Nucleic Acid Testing (NAT) To Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products. Washington, DC, USA: FDA; 2009. Council of Europe. Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646. Strasbourg, France: Council of Europe; 2008.
  10. Lefrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106: 2890-2895.
  11. Türk Dağı H, Özdemir M, Baykan M, Baysal B. Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey. Mikrobiyol Bul 2010; 44: 467-472.
  12. Motor VK, Arıca S, Motor S, Yılmaz N, Evirgen Ö, İnci M, Gökçe C, Önl